🇺🇸 FDA
Pipeline program

Sonelokimab

M1095-axSpA-202

Phase 2 small_molecule active

Quick answer

Sonelokimab for axial spondyloarthritis is a Phase 2 program (small_molecule) at MoonLake Immunotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
MoonLake Immunotherapeutics
Indication
axial spondyloarthritis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials